LAUSR

Whether elderly women over 80 years old with acute coronary syndrome (ACS) should actively receive PCI treatment is still controversial. We assessed the effectiveness and long-term clinical outcomes of PCI in very elderly women patients, and detected predictive factors which contributed to the major adverse cardiovascular and cerebrovascular events (MACCE). Female ACS patients aged ≥80 years were continuously enrolled from the hospital database bank (n=729, a mean age of 83.6±3.1 years). All patients were followed up for MACCE: non-fatal MI, stroke, heart failure (HF) re-hospitalization, cardiovascular (CV) death, and the composite of them. Before and after Propensity Score (PS) Matching (1:1), the incidences of MACCE were compared between female PCI group (n=232) and medical group (n=497). Clinical and coronary artery characteristics were analyzed in PCI treatment patients with (n=56) and without MACCE (n=176). Multivariate Cox regression analysis was performed to identify risk factors which independently associated with MACCE in female PCI patients. A total of 31.8% women (n=232) received PCI treatment in the retrospective study.Compared to medical group, PCI treatment significantly reduced the incidences of non-fatal MI (6.2%, 20.2%, p<0.001), HF re-hospitalization (10.9%, 22.5%, p=0.012), CV death (12.4%, 28.7%, p<0.001) and the composite MACCE (24.0%, 44.2%, p<0.001) after PS matching (129 patients in PCI group vs 129 patients in medical group)during a follow-up period of 36 (23, 48) months. Meanwhile, there were no significant differences in composite MACCE (24.1% vs 19.7%, p=0.232) and CV death (10.8% vs 10.6%, p=0.951) between very elderly women and men (≥80 years old) treated with PCI during the same period. Multivariate Cox analysis revealed that STEMI (HR 1.944, 95% CI 1.11–3.403, p=0.02) and elevated NT-proBNP (HR 1.689, 95% CI 1.029–2.733, p=0.038) were independently associated with the incidence of composite MACCE, as well as adherence to P2Y12 receptor antagonist (HR 0.119, 95% CI 0.051–0.278, p<0.001) and β-blocker (HR 0.452, 95% CI 0.254–0.805, p=0.007) medications may help to attenuate the risk of MACCE within elderly women treated with PCI. In very elderly women with ACS, PCI treatment significantly decreased the risks of MACCE and improves the long-term clinical outcomes.STEMI and elevated NT-proBNP value were independently associated with the increase of the composite MACCE after PCI in this population. Type of funding source: None